0.2475
price down icon3.70%   -0.0095
pre-market  시장 영업 전:  .245   -0.0025   -1.01%
loading

Theriva Biologics Inc 주식(TOVX)의 최신 뉴스

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic - Benzinga

pulisher
Benzinga

Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 4.2% - Defense World

pulisher
Defense World

Theriva Biologics (NYSEAMERICAN:TOVX) Trading Down 4.2% - Defense World

pulisher
Defense World

Get in on Theriva Biologics Inc's (TOVX) buy-in window today! – Sete News - SETE News

pulisher
SETE News

Theriva Biologics Inc [TOVX] moved down -7.55: Why It's Important – The DBT News - The DBT News

pulisher
The DBT News

Closing Figures: Theriva Biologics Inc (TOVX)'s Negative Finish at 0.31, Down -7.55 – DWinneX - The Dwinnex

pulisher
The Dwinnex

Stock Surge: Theriva Biologics Inc (TOVX) Closes at 0.33, Marking a -8.56 Increase/Decrease – DWinneX - The Dwinnex

pulisher
The Dwinnex

FDA grants fast track status to Theriva's cancer drug By Investing.com - Investing.com Canada

pulisher
Investing.com Canada

Theriva™ Biologics anuncia la designación de vía rápida concedida por la FDA estadounidense al VCN-01 para el tratamiento del cáncer de páncreas metastásico

pulisher
GlobeNewswire Inc.

Theriva gets FDA fast track status for VCN-01 for pancreatic cancer (NYSE:TOVX) - Seeking Alpha

pulisher
Seeking Alpha

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - GlobeNewswire

pulisher
GlobeNewswire

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance

pulisher
Yahoo Finance

Sidoti's December Small-Cap Virtual Conference - The Globe and Mail

pulisher
The Globe and Mail

Another Biotech Stealing The Premarket Spotlight - The Globe and Mail

pulisher
The Globe and Mail

Theriva™ Biologics to Participate in the A.G.P. Virtual - GlobeNewswire

pulisher
GlobeNewswire

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics presenta los aspectos operativos más destacados y los resultados financieros del primer trimestre de 2024

pulisher
GlobeNewswire Inc.

Theriva Biologics: Q1 Earnings Snapshot - Houston Chronicle

pulisher
Houston Chronicle

Theriva Biologics Faces Liquidity Crisis: Urgent Capital Needed to Sustain Operations and Clinical Programs ... - TipRanks

pulisher
TipRanks

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire

pulisher
GlobeNewswire

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

pulisher
GlobeNewswire Inc.

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered ... - Yahoo Finance

pulisher
Yahoo Finance

Theriva Biologics' VCN-01 Shows Promise in Pediatric Cancer Trial - TipRanks.com - TipRanks

pulisher
TipRanks

Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Abeona Therapeutics ( - Benzinga

pulisher
Benzinga

Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy - TipRanks.com - TipRanks

pulisher
TipRanks

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

pulisher
GlobeNewswire Inc.

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic ... - Yahoo Finance

pulisher
Yahoo Finance

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Diff - Benzinga

pulisher
Benzinga

Theriva™ Biologics anuncia su presentación en la 27ª Reunión Anual de la Sociedad Americana de Terapia Celular y Génica

pulisher
GlobeNewswire Inc.

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting - Yahoo Finance

pulisher
Yahoo Finance

Theriva Biologics, Inc. (NYSE:TOVX) Q4 2023 Earnings Call Transcript March 25, 2024 - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

pulisher
GlobeNewswire Inc.

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics realizará una teleconferencia y retransmisión por Internet para comentar los aspectos operativos más destacados y los resultados financieros del ejercicio 2023

pulisher
GlobeNewswire Inc.

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

pulisher
GlobeNewswire Inc.

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and ... - Yahoo Finance

pulisher
Yahoo Finance

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

pulisher
GlobeNewswire Inc.

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could - Benzinga

pulisher
Benzinga

Simtra BioPharma to invest $250m in US facility - Pharmaceutical Technology

pulisher
Pharmaceutical Technology

Theriva Biologics Reports Positive Phase 2b Trial Progress - TipRanks.com - TipRanks

pulisher
TipRanks

Theriva Biologics anuncia la recomendación positiva del Comité independiente para la monitorización de los datos de Datos de VIRAGE, el ensayo clínico de fase 2b de VCN-01 en combinación con quimioterapia para el adenocarcinoma pancreático ductal metastásico

pulisher
GlobeNewswire Inc.

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE ... - Yahoo Finance

pulisher
Yahoo Finance

Theriva Biologics participará en la Conferencia Anual de Oncología de B. Riley Securities

pulisher
GlobeNewswire Inc.

US dosing begins in Theriva's VIRAGE pancreatic cancer trial - Clinical Trials Arena

pulisher
Clinical Trials Arena

Why Is AST SpaceMobile (ASTS) Stock Down 28% Today? - InvestorPlace

pulisher
InvestorPlace

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of ... - Yahoo Finance

pulisher
Yahoo Finance

Theriva Biologics Appoints Ramon Alemany, Ph.D., as Senior Vice President of Discovery - citybiz

pulisher
citybiz
$85.02
price up icon 1.81%
$25.78
price down icon 1.57%
$159.38
price down icon 1.97%
$157.30
price down icon 1.93%
$88.44
price down icon 3.95%
$378.30
price down icon 2.25%
자본화:     |  볼륨(24시간):